



# Retraction: Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways

Frontiers Editorial Office\*

A Retraction of the Original Research Article

## OPEN ACCESS

**Approved by:**

Arianna Maffei,  
Stony Brook University, United States

**\*Correspondence:**

Frontiers Editorial Office  
editorial.office@frontiersin.org

**Specialty section:**

This article was submitted to  
Cellular Neurophysiology,  
a section of the journal  
Frontiers in Cellular Neuroscience

**Received:** 23 April 2021

**Accepted:** 23 April 2021

**Published:** 04 June 2021

**Citation:**

Frontiers Editorial Office (2021)  
Retraction: Clematichinenoside  
Serves as a Neuroprotective Agent  
Against Ischemic Stroke: The  
Synergistic Action of ERK1/2 and  
cPKC Pathways.  
*Front. Cell. Neurosci.* 15:699518.  
doi: 10.3389/fncel.2021.699518

**Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways**

by Liu, C., Du, Q., Zhang, X., Tang, Z., Ji, H., and Li, Y. (2016). *Front. Cell. Neurosci.* 9:517.  
doi: 10.3389/fncel.2015.00517

The journal retracts the 12 January 2016 article cited above.

Following publication, it has been brought to our attention that several figures included in the article above appear identical to figures published by the authors in a separate article, “The neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway” (doi: 10.1016/j.neuropharm.2015.02.022), published in *Neuropharmacology*, February 2015. Specifically, the Bax-sham and Bax-AR(32 mg/kg) panels in Figure 2A of the *Frontiers in Cellular Neuroscience* publication appear identical to the D and F panels in Figure 5C of the *Neuropharmacology* publication, respectively. The TUNEL-AR(16 mg/kg) panel in Figure 2A of the *Frontiers in Cellular Neuroscience* publication also appears identical to panel C in Figure 4A of the *Neuropharmacology* publication.

The authors concur with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors, and readers of *Frontiers in Cellular Neuroscience*.

Copyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.